Published • loading... • Updated
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
Summary by BizToc
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
Amgen’s (AMGN) closely watched cardiovascular drug candidate lost a major rival on Sept. 4, when Novartis (NVS) announced that its pelacarsen trial failed to reduce heart attacks and strokes in high-risk patients. The surprising part is that the news triggered a sell-off among AMGN shareholders…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
